An InHouse Event

Funding the Future of Biotech in Australia

Don’t miss this strictly limited numbers InHouse event with InCorp Advisory and Endpoints Capital

Doors open at 5.00pm with networking, including drinks and canapés. The presentation kicks off at 6.00pm, followed by an opportunity to connect with peers and industry leaders.

Join InCorp Advisory and Endpoints Capital for an exclusive information and networking event, focused on the opportunities for Biotech in the Australian market.

At this event, you’ll discover how non-dilutive capital can revolutionise funding for Biotech companies while navigating Australia’s unique financing landscape. You’ll also gain strategic insights on optimising financial roadmaps, minimising risks, particularly around regulation and tax, and maximising resilience.

You’ll hear from InCorp Advisory Partner and CEO, Sameer Kassam, and Endpoints Capital CEO, Andrew Stewart, as they share practical strategies and real-world experiences to help your biotech business thrive.

Numbers are strictly limited! This is also a premium networking opportunity to bring together peers in this vibrant, dynamic industry. Don’t miss your chance to join the exclusive group.

Event Highlights:

Gain insights into the latest Biotech funding opportunities, including undervalued assets and early-stage oncology investments.
Understand defensibility in Biotech: How to prepare and present the business to avoid ATO audits and maximise benefits.
Discover how to balance debt and equity funding to reduce reliance on capital markets and protect your company’s valuation.
Understand how to use R&D funding proactively as part of your long-term financial roadmap, rather than as a last-minute solution.
Enjoy an excellent networking opportunity with industry peers, including an excellent selection of drinks and canapes.

Why attend?

Get actionable insights and practical advice from industry veterans.
Understand the latest and changing trends and strategies in Biotech financing.
Discover how to proactively prepare your company for funding success.

Remember, numbers are strictly limited, so please register to attend at your earliest convenience.

Who should attend?

Biotech company founders and executives.
CFOs, finance leaders, and operations teams in life sciences.
Industry professionals, navigating funding challenges.

Register now

Don’t miss this opportunity to equip yourself with the knowledge and tools to navigate the complexities of biotech financing in today’s dynamic environment.

Meet the hosts

Sameer Kassam

Co-CEO

Andrew Stewart

CEO

About InCorp Advisory

InCorp Advisory Australia is a leading boutique provider, offering a wide range of corporate solutions and professional services across Australia, and is part of the InCorp Global group that spans 9 countries across the Asia Pacific region. Our highly experienced and reputable team of 120+ full-time individuals come from a range of backgrounds across accounting, finance, science, engineering and technology. This breadth of skills and background enables us to provide a responsive and high-quality business advisory and compliance service that is always tailored to specific accounting needs. We work with small-to-medium-sized businesses, ASX-listed companies, family offices, subsidiaries of multinationals groups, high-net-worth individuals, not-for-profits and charities.

About Endpoints Capital

Endpoints Capital was founded to address the funding challenges that Biotechnology companies face by providing a financing solution that benefits biotechs at all stages. Our founders understand the life sciences ecosystem and the challenges – including financing – that Biotechnology companies face getting their treatment or device into the clinic. This has been further compounded by the difficulties in capital markets in recent times.